Novo Nordisk reported DKK13.6B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Bausch Health Companies USD 979M 55M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Novo Nordisk DKK 1.95B 10.94B Jun/2025
Pacira USD 50.74M 3.89M Mar/2026
Sanofi EUR 3.67B 621M Mar/2026
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026